Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy

Scoccianti, Silvia; Paoli, Camilla Delli; Leonulli, Barbara Grilli; Paoletti, L.; Alpi, P.; Caini, Saverio; Barca, R.; Fondelli, S.; Russo, S.; Perna, Marco; Pino, Maria Simona; Martella, Francesca; Furlan, Federica; Bassetti, Andrea; Fioretto, Luisa

doi:10.1016/s1470-2045(21)00427-7

Cited by 10 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the vaccine seems to be safe during RT [ 223 , 225 , 226 ]. The only prospective study by Scoccianti et al confirms this statement [ 224 ].…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role. Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was “Covid AND Radiotherapy” and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.

show abstract

“…Therefore, the vaccine seems to be safe during RT [ 223 , 225 , 226 ]. The only prospective study by Scoccianti et al confirms this statement [ 224 ].…”

Section: Discussionmentioning

confidence: 79%

“…The prospective study of Scoccianti et al showed that Moderna mRNA-1273 vaccine produced good results in patients who underwent RT for both early adverse events and late adverse effects [ 224 ].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

“…The published literature regarding ADRs in cancer patients after COVID-19 vaccine administration mostly shows an increasing trend of systemic ADRs after the second dose. 13,[20][21][22][23][24][25][26][27] We could only find one study conducted in Thailand in which ADRs after the first and second of AZD1222 vaccine doses were evaluated observing the opposite trend. 28 Some articles have also showed an association between gender and the incidence of ADRs after the SARS-CoV-2 vaccines.…”

Section: Discussionmentioning

confidence: 99%

Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain

et al. 2022

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients’ demographics. We selected from our records all 18-years or older solid cancer patients under active treatment vaccinated with the complete three-dose schedule mRNA-1273 vaccine whose adverse drug reactions (ADRs) after each dose were recorded. Medical records were reviewed retrospectively to collect data between April 19, 2021, and December 31, 2021. Patients with documented previous infection by SARS-Cov-2 were excluded. Results: A total of 93 patients met the inclusion criteria. Local ADRs were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic adverse reactions after the third dose, p < 0.001 and between systemic adverse reactions after the second dose and systemic adverse reactions after the third dose, p = 0.001 A significant linear trend, p = 0.012, with a higher Eastern Cooperative Oncology Group (ECOG) score associated with a lower proportion of patients suffering from systemic side effects was found. Women had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016). Conclusion: The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.

show abstract

“…Of this cohort, 33% of patients had no adverse events after the first dose, 38% had no AE after the second dose, and 20% had no AE after the first and second doses. It was concluded that overall, tolerance was not worse in radiotherapy patients compared to controls [ 63 ].…”

Section: Safety Of the Covid-19 Vaccines On The Cancer Patientsmentioning

confidence: 99%

Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges

Almasri

Bshesh

Khan

et al. 2022

Cancers

View full text Add to dashboard Cite

Few guidelines exist for COVID-19 vaccination amongst cancer patients, fostering uncertainty regarding the immunogenicity, safety, and effects of cancer therapies on vaccination, which this review aims to address. A literature review was conducted to include the latest articles covering the immunogenicity and safety of COVID-19 vaccination in patients with solid and hematologic cancers receiving various treatments. Lower seropositivity following vaccination was associated with malignancy (compared to the general population), and hematologic malignancy (compared to solid cancers). Patients receiving active cancer therapy (unspecified), chemotherapy, radiotherapy, and immunosuppressants generally demonstrated lower seropositivity compared to healthy controls; though checkpoint inhibition, endocrine therapy, and cyclin dependent kinase inhibition did not appear to affect seropositivity. Vaccination appeared safe and well-tolerated in patients with current or past cancer and those undergoing treatment. Adverse events were comparable to the general population, but inflammatory lymphadenopathy following vaccination was commonly reported and may be mistaken for malignant etiology. Additionally, radiation recall phenomenon was sporadically reported in patients who had received radiotherapy. Overall, while seropositivity rates were decreased, cancer patients showed capacity to generate safe and effective immune responses to COVID-19 vaccination, thus vaccination should be encouraged and hesitancy should be addressed in this population.

show abstract

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy

Cited by 10 publications

References 4 publications

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain

Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges

Contact Info

Product

Resources

About